Impact of Prior DME Treatment on Aflibercept 8 mg Outcomes

At the 128th Annual American Academy of Ophthalmology (AAO) Meeting in Chicago, Illinois, Sunir J. Garg, MD, Wills Eye Hospital, describes an analysis of the Phase 2/3 PHOTON trial evaluating the effect of prior diabetic macular edema (DME) treatment history on outcomes for aflibercept 8 mg versus 2 mg at 96 weeks.

Watch the video.